Once T-DXd has reached the tumor tissue and is internalized by HER2-positive cells [58], the linker is selectively cleaved by lysosomal cathepsins, releasing the cytotoxic payload and enabling targeted anticancer effects. The gene discussed is ERBB2; the disease is neoplasm.